3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency

Inclusion Criteria: * Subjects between ≥ 18 and ≤ 85 years old. * Subjects who signed written, IRB approved, informed consent form. * Subjects scheduled for urological or gynecological surgical procedures in which the patency of the ureter must be assessed by the surgeon during the procedure Exclusion Criteria: * Subjects with stage 4 or 5 Chronic Kidney Failure as evidenced by a GFR \<30 mL/min/1.73m2 (using the MDRD) or need for dialysis in the near future, or having only 1 kidney. * Subjects with known severe hypersensitivity reactions to IC or other dyes including contrast agents. * Known history of drug or alcohol abuse within 6 months prior to the time of screening visit. * Subjects, as assessed by the Investigator, with conditions/concomitant diseases precluding their safe participation in this study (e.g. major systemic diseases). * Unable to meet specific protocol requirements (e.g., scheduled visits) or subject is uncooperative or has a condition that could lead to non-compliance with the study procedures. * Subject is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol; * Subjects with life expectancy \< 6 months; * Requirement for concomitant treatment that could bias primary evaluation. * Subjects who are pregnant or breast-feeding.